Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Commentary|Videos|June 16, 2024
Dr Trudel on Results From the DREAMM-7 Trial of BVd in R/R Multiple Myeloma
Author(s)Suzanne Trudel, MSc, MD
Suzanne Trudel, MSc, MD, discusses key results and subgroup analyses from the phase 3 DREAMM-7 trial of BVd in relapsed/refractory multiple myeloma.
Advertisement
Suzanne Trudel, MSc, MD, associate professor, University of Toronto; clinician scientist, Princess Margaret Cancer Centre, discusses primary results and subgroup analyses from the phase 3 DREAMM-7 trial (NCT04246047) of belantamab mafodotin (Blenrep), bortezomib (Velcade), and dexamethasone (BVd) vs daratumumab (Darzalex), bortezomib and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma.
Advertisement
Related to this article
Natera has submitted Signatera to Japan's PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.
Adam D. Cohen, MD, overviews phase 1 findings for cevostamab and outlines future research directions for the agent in relapsed/refractory multiple myeloma.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
Dato-DXd was approved in the European Union as monotherapy for patients with first-line metastatic TNBC who are not candidates for immunotherapy.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain
Advertisement
Advertisement
Trending on OncLive
1
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
2
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
3
Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026
4
Docirbrutinib Yields High Response Rates in MCL and CLL
5